Gilead Sciences Inc
NASDAQ: GILD
$92.41
+$1.06 (+1.2%)
Closing Price on November 27, 2024
GILD Articles
The October 15 short interest data have been compared with the previous figures, and short interest mixed in these selected biotech stocks.
Published:
These biotech stocks 24/7 Wall St. has picked stood out from the rest with at least 25% gains over the course of the past week.
Published:
ThinkstockThe U.S. Food and Drug Administration (FDA) issued a warning that hepatitis C treatments, Viekira Pak and Technivie, can cause serious liver injury mostly in patients with underlying...
Published:
Last Updated:
Cowen says the way to play biotech is with large cap sector leaders that can beat earnings estimates. It also thinks third-quarter earnings beats could highlight the risk of not owning biotech now.
Published:
Tuesday's top analyst upgrades, downgrades and initiations include Bluebird Bio, Boston Beer, Etsy, Gilead Sciences, Pfizer, PMC-Sierra and Valeant Pharmaceuticals.
Published:
Last Updated:
The September 30 short interest data have been compared with the previous figures, and short interest increased in most of these selected biotech stocks for this settlement date.
Published:
Given the massive beat-down in the sector, if these companies surpass earnings expectations, the upside could be sizable.
Published:
Wikimedia CommonsIf there was ever a time when investors are thrilled to see the calendar change it could be now. With the fourth quarter just starting, many are more than relieved to put the third...
Published:
Friday’s top analyst upgrades, downgrades and initiations include AIG, Facebook, Gilead Sciences, Google, Regeneron Pharmaceuticals, Twitter, Valeant Pharmaceuticals and Vertex Pharmaceuticals.
Published:
24/7 Wall St. has taken a look at some of the largest biotech companies and highlighted the damage that a single tweet did to them last week.
Published:
The September 15 short interest data have been compared with the previous figures, and short interest in these selected stocks increased across the board for this settlement date.
Published:
After the sell-off, there are now many more solid and well-established dividend-paying companies valued at less than 10 times earnings.
Published:
Friday’s top analyst upgrades, downgrades and initiations include Aetna, Eli Lilly, Gilead Sciences, Royal Gold and Sirius XM.
Published:
The short interest data are out for the August 31 settlement date. Short interest in the selected biotech stocks increased across the board for this settlement date.
Published:
ThinkstockAre biotech companies going to become the next big companies saddled with debt? Most likely not, but two debt offerings will stand out to investors here. The first was a $10 billion...
Published: